191 related articles for article (PubMed ID: 37783294)
21. Role of non-coding RNAs as novel biomarkers for detection of colorectal cancer progression through interaction with the cell signaling pathways.
Esmaeili M; Keshani M; Vakilian M; Esmaeili M; Peymani M; Seyed Forootan F; Chau TL; Göktuna SI; Zaker SR; Nasr Esfahani MH; Ghaedi K
Gene; 2020 Aug; 753():144796. PubMed ID: 32450203
[TBL] [Abstract][Full Text] [Related]
22. Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.
Moafian Z; Maghrouni A; Soltani A; Hashemy SI
Mol Biol Rep; 2021 May; 48(5):4797-4811. PubMed ID: 34057685
[TBL] [Abstract][Full Text] [Related]
23. GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial‑mesenchymal transition through PI3K/AKT signaling activation.
Ji B; Feng Y; Sun Y; Ji D; Qian W; Zhang Z; Wang Q; Zhang Y; Zhang C; Sun Y
Oncol Rep; 2018 Oct; 40(4):1885-1896. PubMed ID: 30066935
[TBL] [Abstract][Full Text] [Related]
24. Identification of candidate biomarkers and therapeutic drugs of colorectal cancer by integrated bioinformatics analysis.
Zheng Z; Xie J; Xiong L; Gao M; Qin L; Dai C; Liang Z; Wang Y; Xue J; Wang Q; Wang W; Li X
Med Oncol; 2020 Oct; 37(11):104. PubMed ID: 33078282
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-760 inhibits the biological progression of colorectal carcinoma by directly targeting FOXA1 and regulating epithelial-to-mesenchymal transition and PI3K/AKT signaling pathway.
Cong K; Li CG; Wei YH; Zhang K; Xu HB
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5730-5740. PubMed ID: 31298352
[TBL] [Abstract][Full Text] [Related]
26. PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407.
Tan X; Chen S; Wu J; Lin J; Pan C; Ying X; Pan Z; Qiu L; Liu R; Geng R; Huang W
Cell Death Dis; 2017 Mar; 8(3):e2686. PubMed ID: 28300833
[TBL] [Abstract][Full Text] [Related]
27. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
28. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
29. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer.
Zhang Y; Wang Y; Zhang B; Li P; Zhao Y
Biomed Pharmacother; 2023 Jul; 163():114786. PubMed ID: 37119736
[TBL] [Abstract][Full Text] [Related]
30. Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment.
Maurya NS; Mani A
Curr Top Med Chem; 2023; 23(30):2821-2843. PubMed ID: 37317918
[TBL] [Abstract][Full Text] [Related]
31. Colorectal Cancer Biology, Diagnosis, and Therapeutic Approaches.
Dariya B; Aliya S; Merchant N; Alam A; Nagaraju GP
Crit Rev Oncog; 2020; 25(2):71-94. PubMed ID: 33389859
[TBL] [Abstract][Full Text] [Related]
32. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer.
Wu J; Xie N; Xie K; Zeng J; Cheng L; Lei Y; Liu Y; Song L; Dong D; Chen Y; Zeng R; Nice EC; Huang C; Wei Y
Carcinogenesis; 2013 Dec; 34(12):2861-9. PubMed ID: 23803691
[TBL] [Abstract][Full Text] [Related]
33. Potentials of long non-coding RNAs as biomarkers of colorectal cancer.
Lv Y; Wang Y; Zhang Z; Bao J; Su H
Clin Transl Oncol; 2022 Sep; 24(9):1715-1731. PubMed ID: 35581419
[TBL] [Abstract][Full Text] [Related]
34. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
Zhang X; Hou H; Jiang M; Zhang X
Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
[TBL] [Abstract][Full Text] [Related]
35. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
36. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Lin L; Zhang Z; Zhang W; Wang L; Wang J
Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
38. Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
Chandramohan K; Balan DJ; Devi KP; Nabavi SF; Reshadat S; Khayatkashani M; Mahmoodifar S; Filosa R; Amirkhalili N; Pishvaei S; Sargazi-Aval O; Nabavi SM
Eur J Pharmacol; 2023 Jun; 949():175699. PubMed ID: 37011722
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNAs in colorectal cancer: Novel oncogenic mechanisms and promising clinical applications.
Yang Y; Yan X; Li X; Ma Y; Goel A
Cancer Lett; 2021 Apr; 504():67-80. PubMed ID: 33577977
[TBL] [Abstract][Full Text] [Related]
40. MiR-93/HMGB3 regulatory axis exerts tumor suppressive effects in colorectal carcinoma cells.
Gu M; Jiang Z; Li H; Peng J; Chen X; Tang M
Exp Mol Pathol; 2021 Jun; 120():104635. PubMed ID: 33773992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
